Determination of avibactam and ceftazidime in human plasma samples by LC-MS

被引：45

作者：

Sillen, Henrik ^{[1
]}

Mitchell, Richard ^{[2
]}

Sleigh, Rebecca ^{[3
]}

Mainwaring, Guy ^{[4
]}

Catton, Katherine ^{[2
]}

Houghton, Richard ^{[5
]}

Glendining, Karen ^{[4
]}

机构：

[1] AstraZeneca R&D, Molndal, Sweden

[2] Covance, Harrogate HG3 1PY, N Yorkshire, England

[3] LGC, Fordham CB7 5WW, Cambs, England

[4] AstraZeneca, Macclesfield SK10 2NA, Cheshire East, England

[5] Quotient Biores, Rushden NN10 6ER, Northants, England

来源：

BIOANALYSIS | 2015年 / 7卷 / 12期

关键词：

LACTAMASE-PRODUCING ENTEROBACTERIACEAE; IN-VITRO ACTIVITY; GRAM-NEGATIVE BACTERIA; PSEUDOMONAS-AERUGINOSA; KLEBSIELLA-PNEUMONIAE; LIQUID-CHROMATOGRAPHY; NXL104; COMBINATIONS; BETA-LACTAMASES; CARBAPENEMASES; INFECTIONS;

D O I：

10.4155/bio.15.76

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Aim: Avibactam, a novel non--lactam -lactamase inhibitor co-administrated with the -lactam antibiotic ceftazidime, is in clinical development. The need to evaluate its PK and PD requires accurate and reliable bioanalytical methods. Methods: We describe LC-MS/MS methods for the determination of avibactam and ceftazidime in human plasma. Avibactam was extracted using weak anionic exchange solid-phase extraction and analyzed on an amide column. Ceftazidime was extracted using protein precipitation and analyzed on a C18 column. Calibration curves were established over 10-10,000 ng/ml (avibactam) and 43.8-87,000 ng/ml (ceftazidime). Results & conclusion: Method validation, cross-validation between three laboratories and incurred sample re-analysis demonstrated method robustness. The methods were successfully applied to multiple clinical studies.

引用

收藏

页码：1423 / 1434

页数：12

相关论文

共 27 条

[1] In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae [J].

Aktas, Z. ;

Kayacan, C. ;

Oncul, O. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (01) :86-89

[2]

[Anonymous], 2001, Guidance for industry - bioanalytical method validation

[3] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].

Boucher, Helen W. ;

Talbot, George H. ;

Bradley, John S. ;

Edwards, John E., Jr. ;

Gilbert, David ;

Rice, Louis B. ;

Scheld, Michael ;

Spellberg, Brad ;

Bartlett, John .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12

[4] Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types [J].

Castanheira, Mariana ;

Sader, Helio S. ;

Farrell, David J. ;

Mendes, Rodrigo E. ;

Jones, Ronald N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) :4779-4785

[5] Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model [J].

Coleman, Ken ;

Levasseur, Premavathy ;

Girard, Anne-Marie ;

Borgonovi, Monica ;

Miossec, Christine ;

Merdjan, Henri ;

Drusano, George ;

Shlaes, David ;

Nichols, Wright W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) :3366-3372

[6] Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam [J].

Das, Shampa ;

Armstrong, Jon ;

Mathews, David ;

Li, Jianguo ;

Edeki, Timi .

JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03) :331-340

[7]

Deshpando DA, 2004, CURRENT SCI, V87, P1684

[8] Determination of ceftazidime in plasma using high-performance liquid chromatography and electrochemical detection - Application for individualizing dosage regimens in elderly patients [J].

Guitton, J ;

Laffont, A ;

Bruzeau, J ;

Rochet-Mingret, L ;

Bonnefoy, M ;

Bureau, J .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1998, 719 (1-2) :151-157

[9] Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa [J].

Kanj, Souha S. ;

Kanafani, Zeina A. .

MAYO CLINIC PROCEEDINGS, 2011, 86 (03) :250-259

[10] Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases [J].

Lagace-Wiens, P. R. S. ;

Tailor, F. ;

Simner, P. ;

DeCorby, M. ;

Karlowsky, J. A. ;

Walkty, A. ;

Hoban, D. J. ;

Zhanel, G. G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) :2434-2437